Therapy

SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process

Retrieved on: 
Wednesday, May 18, 2022 - 11:45am
Oncology, Health, Stem Cells, Genetics, Clinical Trials, Biotechnology, Regenerative medicine, Phenotype, RNA transfection, Health, Stem cell, Population, Autoimmunity, Private Securities Litigation Reform Act, Microarray, POC, TAC, U.S. Securities and Exchange Commission, HSC, Degenerative disease, HPV16, Patient, Infection, Immune tolerance, Stemcell Technologies, RUO, Monocyte, Society, COVID-19, B2M, Research, Gene, CFC, Electroporation, TCR, Coeliac disease, AAC, NK, Time, Toxicity, CRISPR, CCR5, American Society of Gene and Cell Therapy, Risk, Royal Naval Patrol Service, Therapy, Confidentiality, Cell, Cancer, NYSE, Annual report, SQZ, Vaccine, Pharmaceutical industry, Fine chemical

SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.

Key Points: 
  • SQZ Biotechnologies (NYSE: SQZ) announced today that the companys first generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.
  • Our current clinical manufacturing process is under 24 hours - comparatively faster than other cell therapy manufacturing approaches.
  • We look forward to its planned first clinical use in our red blood cell derived SQZ TAC program for celiac disease.
  • The SQZ POC manufacturing system integrates and automates, among other things, cell isolation, cell washing, Cell Squeeze intracellular delivery technology, and product filling.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors

Retrieved on: 
Wednesday, May 18, 2022 - 5:00pm
Legal, Professional Services, Chemistry, Company, Financial Times, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, SCAS, News, Migraine, Person, Insurance, Information technology, NASDAQ, Endpoint security, Bloomberg Businessweek, The Wall Street Journal, Therapy, DOJ, Associated Press, Real estate investment trust, FDA, CMC, Industry, GPM, Program, Press, NDA, SEC, Publication, Medical device, Pharmaceutical industry, Forbes, Reuters

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Axsome Therapeutics, Inc. (Axsome or the Company) (NASDAQ: AXSM ) investors concerning the Companys possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Axsome Therapeutics, Inc. (Axsome or the Company) (NASDAQ: AXSM ) investors concerning the Companys possible violations of the federal securities laws.
  • On this news, Axsomes stock fell $5.22, or 7%, to close at $69.51 per share on November 5, 2020, thereby injuring investors.
  • On this news, Axsomes stock fell $8.60, or 22%, to close at $30.50 per share on April 25, 2022, thereby injuring investors further.
  • Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation.

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease

Retrieved on: 
Wednesday, May 18, 2022 - 11:30am
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Patient, Knowledge, NASDAQ, Brain, KRTX, Psychiatry, Therapy, Psychosis, Karuna, Pharmaceutical industry

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m.
  • The one-hour webcast event will highlight progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for the treatment of psychosis in Alzheimers disease.
  • The event will feature presentations from members of Karunas leadership team.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

Retrieved on: 
Wednesday, May 18, 2022 - 1:00pm
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Infectious Diseases, Clinical Trials, Diabetes, Risk, PST, Infection, DFO, MD, American Diabetes Association, Multimedia, Patient, Phage therapy, Therapy, Trial of the century, NIH, FDA, United States Department of Defense, Time, APT, Osteomyelitis, Safety, Technology, National, Amputation, Investigational New Drug, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220518005275/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220518005275/en/
    Vial of phage from APTs phage bank for evaluation in treatment of bacterial infections.
  • Phages from the APT phage bank are precision-matched to the patients infections through a proprietary phage susceptibility test (PST) that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.
  • APT has ongoing clinical trials to address substantial unmet patient needs in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO).

Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meeting

Retrieved on: 
Wednesday, May 18, 2022 - 11:01am
Health, Genetics, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, Death, Cirrhosis, Cas9, Transplant, Genetic engineering, Aminoacyl tRNA synthetases, class I, CTL, Patient, Kinetics, Gene editing, FIX, Liver, Society, FRG, Hyperfunction, Cell, Gene, Mouse, Lists of diseases, Liver disease, NK, Instagram, Hepatocyte, Amby Burfoot, LinkedIn, Twitter, Factor IX, Liver failure, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Vaccine

Ambyss proprietary platform enables the first and only development and manufacture of functional human hepatocytes, unlocking the full potential of hepatocyte replacement therapy.

Key Points: 
  • Ambyss proprietary platform enables the first and only development and manufacture of functional human hepatocytes, unlocking the full potential of hepatocyte replacement therapy.
  • "Our new data show that Ambys is capable at efficient genetic modification of primary human hepatocytes, unleashing a powerful combination of cell and gene therapy in hepatocytes, said Ron Park, M.D., Chief Executive Officer of Ambys Medicines.
  • "The universal hepatocyte data presented today coupled with the data on our hyperfunctional human hepatocyte program and in vivo bioreactor platform presented earlier this week further validate our breakthrough replacement cell therapy approach for severe liver diseases.
  • Ambys Medicines is focused on pioneering cell replacement therapies for patients with liver failure.

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

Retrieved on: 
Wednesday, May 18, 2022 - 11:00am
Biotechnology, Pharmaceutical, Genetics, Health, Venture round, Pain, Disease, AMN, Mass, Patient, Quality of life, Therapy, ABCD1, Lists of diseases, Monogenic, Research, FDA, Hereditary spastic paraplegia, Primate, AAV, Man, Sexual dysfunction, Mutation, Adrenoleukodystrophy, Incontinence, Tissue, Pharmaceutical industry, Vaccine

SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures.

Key Points: 
  • SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus (AAV)-based therapies for the treatment of devastating, inherited neurological conditions, today announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures.
  • Since our initial investment, SwanBio has made excellent progress, including rapidly advancing its lead program for AMN toward the clinic.
  • We are excited by the potential we see in this business to become a leading gene therapy company, delivering life-changing treatments to patients with debilitating neurological disorders.
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.

ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

Retrieved on: 
Wednesday, May 18, 2022 - 8:45pm
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Inflammation, B cell, RNA transfection, Population, American Thoracic Society, Infection, International Conference on Emerging Infectious Diseases, Patient, Cystic fibrosis, Urinary tract infection, HBE, Cystic fibrosis transmembrane conductance regulator, Therapy, Liver, Â, Cell, Lists of diseases, ATS, Conference, SORT, Mucus, Technology, Recode, CF, LinkedIn, Twitter, LNP, Tissue, Vaccine, CFTR

ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today presented encouraging new preclinical data from the companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022 in San Francisco.

Key Points: 
  • ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today presented encouraging new preclinical data from the companys inhaled mRNA-based therapeutic program for cystic fibrosis (CF) at the American Thoracic Society (ATS) 2022 International Conference, taking place May 13-18, 2022 in San Francisco.
  • Full details from the preclinical CF data can be accessed via the Presentations section on the companys website.
  • Cystic fibrosis (CF) is a progressive, genetic disease which causes persistent lung infections and respiratory failure.
  • CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 100,000 people worldwide.

METiS Joins the Roche Accelerator

Retrieved on: 
Wednesday, May 18, 2022 - 12:00pm
Biotechnology, Pharmaceutical, Health, Health, API, AI, Patient, Excipient, Biotechnology, Roche, Drug development, Machine learning, Therapy, Drug discovery, CEO, Fine chemical, Metis

METiS today announced officially joining the Roche Accelerator with the goal to tap into Roches global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai.

Key Points: 
  • METiS today announced officially joining the Roche Accelerator with the goal to tap into Roches global scientific expertise, laboratory facilities and foster collaboration discussions on formulation development and optimization with Roche Innovation Center Shanghai.
  • "We are excited to become a member of the Roche Accelerator and to establish a closer connection with a global leader in healthcare like Roche," said Chris Lai, co-founder and CEO of METiS.
  • We look forward to testing METiS proprietary AiTEM platform together and exploring deeper collaboration opportunities to bring optimized therapeutics to patients around the world.
  • Dr. Qiusong Tang, Head of Roche Accelerator, said: We have been witnessing digitalization and AI along the entire pharma R&D value chain, and Im very glad to welcome METiS as the first Roche Accelerator portfolio start-up focusing on AI.

Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

Retrieved on: 
Wednesday, May 18, 2022 - 1:45pm
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Mirati, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Food, FAK, U.S. Securities and Exchange Commission, KRAS, ARAF, Patient, Pancreatic Cancer Action Network, Science, RAS, Cancer, BRAF, Oncology, Volunteering, NSCLC, Research, MEK, Patent, Award, Breakthrough therapy, Industry, Government, CRAF, RAF, Verastem Oncology, Security (finance), Pancreatic cancer, SEC, Amgen, RAMP, CEO, Pharmaceutical industry, Vaccine, Medical imaging

We are looking forward to partnering with them to determine whether their investigational treatment combination will be beneficial to patients.

Key Points: 
  • We are looking forward to partnering with them to determine whether their investigational treatment combination will be beneficial to patients.
  • We are honored to have been selected for this important award that will expand our development program for VS-6766 and defactinib to evaluate the combination in patients with metastatic pancreatic cancer, said Louis Denis, Chief Medical Officer at Verastem Oncology.
  • PanCAN created the Therapeutic Accelerator Award as part of its innovative approach to pancreatic cancer research.
  • The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients.

Bicara Therapeutics to Present Clinical Data from Lead Bifunctional Antibody Program, BCA101, at ASCO 2022 Annual Meeting

Retrieved on: 
Wednesday, May 18, 2022 - 12:00pm
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Immunotherapy, Annual general meeting, Tumor microenvironment, Patient, PD-1, Therapy, Society, American Society of Clinical Oncology, Recurrence, Neoplasm, ASCO, TGF, EGFR, Cetuximab, Vaccine

The meeting is being held in Chicago, Illinois and virtually from June 3-7, 2022.

Key Points: 
  • The meeting is being held in Chicago, Illinois and virtually from June 3-7, 2022.
  • Promising preclinical data suggest that BCA101 is superior to the anti-EGFR antibody cetuximab in preventing tumor recurrence, as well as in restoring immune activation.
  • Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of immunotherapy.
  • Bicaras lead asset, BCA101, a first-in-class EGFR / TGF--trap bifunctional antibody, is currently enrolling patients in a Phase 1/1b study.